Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07128251 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a single-arm, multicenter, exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection in patients with unresectable, non-metastatic HCC. The primary endpoint is PFS as assessed by the investigator based on RECIST v1.1 criteria.
Trial Details
NCT Number NCT07128251
Lead Sponsor Anhui Provincial Hospital
Collaborators: Qilu Hospital of Shandong University, Henan Provincial People's Hospital, First Affiliated Hospital of Guangxi Medical University, Shanxi Province Cancer Hospital, Xi'an International Medical Center Hospital, The Second Affiliated Hospital of Harbin Medical University
Conditions
(from sponsor)		 Hepatocellular Carcinoma (HCC), Immunotherapy, PD-1, CTLA-4, TACE
Related terms Carcinoma, Hepatocellular, Diabetes Mellitus, Insulin-Dependent, 12
Enrollment 47 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov